|
|
||||||||
The Annals of Thoracic Surgery, Vol 56, 931-936, Copyright © 1993 by The Society of Thoracic Surgeons
YA Louagie, J Jamart, P Eucher, M Buche and JC Schoevaerdts
Patients undergoing mitral valve replacement (MVR) using a bioprosthesis
are frequently placed on long-term anticoagulant treatment, and thereby
lose the main advantage conferred by the bioprosthesis. To assess
predictive factors of the need for long-term anticoagulant treatment, 100
consecutive patients surviving bioprosthetic MVR between 1977 and 1987 were
followed up. The estimated thromboembolism-free survival was 88.9% +/- 3.6%
after 6 years of follow-up. Preoperative risk factors for thromboembolism
were supraventricular arrhythmia (p = 0.013) and a history of
thromboembolism (p = 0.039). Among the preoperative and postoperative
factors, only postoperative rhythm significantly influenced (p = 0.007) the
thromboembolism-free survival, as determined by Cox regression analysis.
Permanent anticoagulant treatment was instituted in 39 patients.
Preoperative and peroperative risk factors associated with the need for
long-term anticoagulant treatment, as evidenced by Fisher linear
discriminant analysis, were supraventricular arrhythmia (p < 0.001),
septal myotomy (p = 0.013), and predominant mitral stenosis (p = 0.013).
Thus, in those patients with predominant mitral stenosis and
supraventricular arrhythmia preoperatively, the subsequent need for
permanent postoperative anticoagulant treatment is high, and the
implantation of a mechanical valve is therefore recommended, providing
there are no strict contraindications to anticoagulant treatment.
ARTICLES
Mitral valve Carpentier-Edwards bioprosthetic replacement, thromboembolism, and anticoagulants
Division of Cardiovascular and Thoracic Surgery, University Hospital of Mont Godinne (Yvoir), Belgium.
This article has been cited by other articles:
![]() |
D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nowell, E. Wilton, H. Markus, and M. Jahangiri Antithrombotic therapy following bioprosthetic aortic valve replacement Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 578 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.M. Sundt, K.J. Zehr, J.A. Dearani, R.C. Daly, C.J. Mullany, C.G.A. McGregor, F.J. Puga, T.A. Orszulak, and H.V. Schaff Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1024 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves Chest, January 1, 2001; 119(1_suppl): 220S - 227S. [Full Text] [PDF] |
||||
![]() |
M. Emir, G. Uzunonat, B. Yamak, A T. Ulus, M K. Gol, Z. Iscan, S F. Katircioglu, B. Mavitas, O. Tasdemir, and K. Bayazit Effects of Pregnancy on Long-Term Follow-Up of Mitral Valve Bioprostheses Asian Cardiovasc Thorac Ann, September 1, 1998; 6(3): 174 - 178. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |